United Health Products, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that United Health Products, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $37.5K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $59 | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $643 | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | $4.9K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $34.9K | Jul 9, 2020 |
| FY2019 | Dec 31, 2017 | $183.2K | Jul 9, 2020 |
| FY2017 | Dec 31, 2016 | $242.0K | Apr 17, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $0 | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $18.9K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $34 | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $448 | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | $3.6K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $12.6K | Jul 9, 2020 |
| FY2019 | Dec 31, 2017 | $82.2K | Jul 9, 2020 |
| FY2017 | Dec 31, 2016 | $124.1K | Apr 17, 2018 |
| FY2016 | Dec 31, 2015 | $25.8K | Jun 1, 2017 |
| FY2015 | Dec 31, 2014 | $79.7K | May 13, 2016 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.67M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($2.00M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($2.62M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($1.69M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($30.55M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($15.71M) | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | ($6.60M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($5.40M) | Jul 9, 2020 |
| FY2019 | Dec 31, 2017 | ($1.47M) | Jul 9, 2020 |
| FY2017 | Dec 31, 2016 | ($535.7K) | Apr 17, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.26M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($2.01M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($2.43M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($2.80M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($29.80M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($14.85M) | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | ($6.09M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($1.90M) | Jul 9, 2020 |
| FY2019 | Dec 31, 2017 | ($928.4K) | Jul 9, 2020 |
| FY2017 | Dec 31, 2016 | ($517.5K) | Apr 17, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $269.9K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $355.9K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $598.8K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $624.6K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $237.5K | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $245.2K | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | $666.4K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $77.0K | Jul 9, 2020 |
| FY2019 | Dec 31, 2017 | $19.9K | Jul 9, 2020 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.99M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $1.65M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $1.83M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $2.20M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $29.56M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $14.60M | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | $5.43M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $1.83M | Jul 9, 2020 |
| FY2019 | Dec 31, 2017 | $990.7K | Jul 9, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.19M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($1.19M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($2.20M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($619.7K) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($828.1K) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($1.33M) | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | ($1.77M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($1.28M) | Jul 9, 2020 |
| FY2019 | Dec 31, 2017 | ($649.7K) | Jul 9, 2020 |
| FY2017 | Dec 31, 2016 | ($473.4K) | Apr 17, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $0 | Apr 1, 2022 |
| FY2021 | Dec 31, 2020 | $101.4K | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Mar 30, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $316.7K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $270.0K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $284.6K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $350.5K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $26.8K | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $217.1K | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | $93.5K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $113.3K | Jul 9, 2020 |
| FY2019 | Dec 31, 2017 | $239.8K | Jul 9, 2020 |
| FY2017 | Dec 31, 2016 | $197.0K | Apr 17, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.19M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $2.71M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $2.00M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $2.42M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.17M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $1.17M | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | $997.3K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $263.9K | Jul 9, 2020 |
| FY2019 | Dec 31, 2017 | $792.2K | Jul 9, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.88M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($2.44M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | ($1.71M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2022 | ($2.06M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2021 | ($1.14M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | ($953.3K) | Mar 28, 2023 |
| FY2021 | Dec 31, 2019 | ($903.8K) | Apr 1, 2022 |
| FY2020 | Dec 31, 2018 | ($150.7K) | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | ($552.4K) | Jul 9, 2020 |
| FY2019 | Dec 31, 2016 | ($546.0K) | Jul 9, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($81.37M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($78.70M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($76.70M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($74.08M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($72.39M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($41.84M) | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | ($26.13M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($19.53M) | Jul 9, 2020 |
| FY2019 | Dec 31, 2017 | ($14.12M) | Jul 9, 2020 |
| FY2017 | Dec 31, 2016 | ($12.80M) | Apr 17, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $13.4K | Mar 28, 2023 |
| FY2022 | Dec 31, 2021 | $21.8K | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $46.1K | Apr 1, 2022 |
| FY2021 | Dec 31, 2019 | $16.6K | Apr 1, 2022 |
| FY2020 | Dec 31, 2018 | $31.3K | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | $189.9K | Jul 9, 2020 |
| FY2019 | Dec 31, 2016 | $29.4K | Jul 9, 2020 |
| FY2017 | Dec 31, 2015 | $1.5K | Apr 17, 2018 |
| FY2016 | Dec 31, 2014 | $8.3K | Jun 1, 2017 |
| FY2015 | Dec 31, 2013 | $1.9K | May 13, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | 0 | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | 0 | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Apr 17, 2018 |
| FY2016 | Dec 31, 2015 | 0 | Jun 1, 2017 |
| FY2015 | Dec 31, 2014 | 0 | May 13, 2016 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 28, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 258.69M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 252.41M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 244.78M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 230.87M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 228.67M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | 189.36M | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | 178.06M | Mar 30, 2021 |
| FY2018 | Dec 31, 2018 | 171.79M | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | 164.97M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 153.78M | Apr 17, 2018 |